Results 81 to 90 of about 1,655 (156)

Hemorheological and metabolic consequences of renal ischemia-reperfusion and their modulation by N,N-dimethyltryptamine on a rat model [PDF]

, 2018
K
Bidiga, László, Deák, Ádám, Frecska, Ede, Ghanem, Souleiman, Magyar, Zsuzsanna, Mester, Anita, Nemes, Balázs Áron, Németh, Norbert, Pető, Katalin, Somogyi, Viktória, Tánczos, Bence   +10 more
core   +1 more source

Extended‐release buprenorphine treatment for opioid use disorder: A mixed‐methods study of response and experience

Addiction, Volume 120, Issue 10, Page 2055-2066, October 2025.
Abstract Background and aims An investigation of 24 weeks of extended‐release buprenorphine (BUP‐XR; Sublocade®) treatment for adults with opioid use disorder (OUD). Study aims were to characterise variations in clinical response, investigate personal factors influencing BUP‐XR experience and identify opportunities to tailor treatment interventions ...
Natalie Lowry, Andrew McKechnie, Edward Day, Eilish Gilvarry, Fiona Cowden, Rachel Evans, Rosie Locke, Robbie Murray, Rob Vanderwaal, Stacey Johnstone, Zoe Hoare, Michael Kelleher, Luke Mitcheson, John Marsden   +13 more
wiley   +1 more source

Psychedelics, Harm Reduction, and Life's Big Questions: Making Sense of Spirituality and Religion After the Journey

Anthropology of Consciousness, Volume 36, Issue 2, Fall 2025.
ABSTRACT The interplay between psychedelic use, mental health, and spiritual, religious, or ‘mystical’ experiences continues to be investigated through clinical research. While many studies focus on general mechanisms underlying these compounds, analysis of real‐life accounts from individuals is underrepresented.
Lisa L. Gezon, Kenton Bartlett
wiley   +1 more source

Psilocybin as Transformative Fast‐Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms

Fundamental &Clinical Pharmacology, Volume 39, Issue 4, August 2025.
ABSTRACT In the 1950s–60s, serotonergic psychedelic drugs were studied as potential adjuvants to psychotherapy to treat addiction and alcoholism. However, starting in the 70s, preclinical and clinical studies on psychedelics stopped for decades because legislation controlled its recreational use, citing their hallucinogenic and psychotomimetic effects,
Makiath Adebo, Mathilda Bonnet, Ons Laouej, Celine Defaix, Josephine C. McGowan, Florence Butlen‐Ducuing, Denis J. David, Erwan Poupon, Laurent Tritschler, Alain M. Gardier   +9 more
wiley   +1 more source

The Birth of the Psychedelic Industry: Capitalising on the Psychedelic Renaissance

Future Humanities, Volume 3, Issue 1, May 2025.
ABSTRACT The resurgence of psychedelic medicine, often termed ‘the psychedelic renaissance,’ marks a profound shift from decades of repressed research to a burgeoning field characterised by significant scientific, regulatory, and economic transformations.
Minsu Yoo, Sofia Sakopoulos
wiley   +1 more source

Subchronic vortioxetine enhances cortical activity [PDF]

, 2016
Vortioxetine (VOR) is a multimodal antidepressant drug. VOR is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial agonist, 5-HT1A-R agonist, and serotonin transporter (SERT) inhibitor.
Artigas, Francesc, Celada, Pau, Riga, Maurizio, Sánchez, Connie, Teruel-Martí, Vicent   +4 more
core   +1 more source

Safety, Pharmacokinetics, and Pharmacodynamics of a 6‐h N,N‐Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Clinical and Translational Science, Volume 18, Issue 5, May 2025.
ABSTRACT The serotonergic psychedelic N,N‐dimethyltryptamine (DMT) presumably stimulates neuroplasticity in vitro and in vivo, by which it may exert neuroprotective effects during acute ischemic stroke. Since neuroplasticity has been implicated in the mechanism of action of rehabilitative therapy in stroke recovery, a pharmacological augmentation ...
Katelijne V. van der Heijden, Rob G. J. A. Zuiker, Marije E. Otto, Christopher S. Bryan, Nancy Stewart, Christopher Stillwell, Marieke L. De Kam, Marloes B. van Leuken, Joop M. A. van Gerven, Gabriel E. Jacobs   +9 more
wiley   +1 more source

Neurotoxic and Neuroprotective Effects of Psychedelics in a Human Neuroblastoma Cell Model

RevSALUS
Psychedelic compounds, including psilocybin, psilocin, lysergic acid diethylamide (LSD), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), and mescaline, have long been recognized for their recreational effects and involvement in forensic cases.
Andreia Machado Brito da Costa, Ricardo Jorge Dinis-Oliveira, Áurea Madureira-Carvalho, Diana Dias-da-Silva   +3 more
doaj   +1 more source

The bridge between classical and ‘synthetic’/chemical psychoses: towards a clinical, psychopathological and therapeutic perspective [PDF]

, 2019
© 2019 Orsolini, Chiappini, Papanti, De Berardis, Corkery and Schifano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Chiappini, Stephania, Corkery, John Martin, De Berardis, Domenico, Orsolini, Laura, Papanti, Duccio, Schifano, Fabrizio   +5 more
core   +2 more sources

Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression

Nature Communications
Psilocybin, ketamine, and MDMA are psychoactive compounds that exert behavioral effects with distinguishable but also overlapping features. The growing interest in using these compounds as therapeutics necessitates preclinical assays that can accurately ...
Farid Aboharb, Pasha A. Davoudian, Ling-Xiao Shao, Clara Liao, Gillian N. Rzepka, Cassandra Wojtasiewicz, Jonathan Indajang, Mark Dibbs, Jocelyne Rondeau, Alexander M. Sherwood, Alfred P. Kaye, Alex C. Kwan   +11 more
doaj   +1 more source